CD7 expression tied to poorer outcomes with newly diagnosed leukemia

CD7 expression tied to poorer outcomes with newly diagnosed leukemia
CD7 expression tied to poorer results with recently identified leukemia

CD7 expression is related with poorer outcomes in people with freshly identified acute myeloid leukemia (AML), according to a analyze released on the internet April eleven in the British Journal of Haematology.

Wei-Ying Jen, B.M., B.Ch., from the College of Texas MD Anderson Cancer Middle in Houston, and colleagues collected circulation cytometry knowledge on 901 with AML and examined aberrant CD7 expression on leukemic blasts.

The researchers discovered that 29.2% experienced blasts optimistic for CD7. Adverse risk was more most likely (sixty four.six as opposed to 55.6%) and favorable hazard was much less likely (fifteen.two as opposed to 24.one%) with CD7-beneficial AML by European LeukemiaNet 2022 criteria.

On top of that, over-all survival was inferior (11.9 as opposed to 19.0 months). Moderate instability around time was viewed, with 30.4% losing and 19.% attaining CD7 at relapse.

“In summary, we report on a substantial population of AML with consideration to CD7 expression, genomic profiles and patient outcomes,” the authors create.

“The retrospective nature of the analyze and the range of connected cytomolecular features involve a significant sample dimensions, and the identification of any associations will have to have even more analysis and confirmation in impartial datasets.”

A lot more details: Wei‐Ying Jen et al, Traits and results of acute myeloid leukaemia patients with baseline CD7 expression, British Journal of Haematology (2024). DOI: ten.1111/bjh.19446

© 2024 HealthDay. All rights reserved.

Read More

You May Also Like